For research use only. Not for therapeutic Use.
CY 208-243 is a selective dopamine D1 receptor agonist which exhibits antiparkinsonian activity[1].
Pretreatment with CY 208-243 (2.5 mg/kg; s.c.) prevents the increase of DA release and metabolism induced by the D-1 antagonist, SCH 23390 (0.05 mg/kg; s.c.)[1].
| Catalog Number | M008359 |
| CAS Number | 100999-26-6 |
| Synonyms | (2R,11R)-10-methyl-10,15-diazapentacyclo[11.6.1.02,11.03,8.016,20]icosa-1(20),3,5,7,13,16,18-heptaene |
| Molecular Formula | C19H18N2 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H18N2/c1-21-11-12-5-2-3-6-14(12)19-15-7-4-8-16-18(15)13(10-20-16)9-17(19)21/h2-8,10,17,19-20H,9,11H2,1H3/t17-,19-/m1/s1 |
| InChIKey | WRNKIDLXXXIELU-IEBWSBKVSA-N |
| SMILES | CN1CC2=CC=CC=C2C3C1CC4=CNC5=CC=CC3=C45 |
| Reference | [1]. Imperato A, et al. CY 208-243, a novel dopamine D-1 receptor agonist, fails to modify dopamine release in freely moving rats. Eur J Pharmacol. 1989 Jan 24;160(1):155-8. [2]. Temlett JA, et al. The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Eur J Pharmacol. 1988 Nov 1;156(2):197-206. |
